First-in-human Study of RLY-2608, a Pan-Mutant and Isoform Selective PI3Kα Inhibitor, As a Single Agent in Patients (pts) with Advanced Solid Tumors and in Combination with Fulvestrant in Pts with Advanced Breast Cancer.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined